Another study tested the efficacy of a monoclonal anti-mature IL-18 antibody in DSS colitis mice found that it improved acute and chronic DSS colitis, reduced production of IFNγ and TNFα and ameliorated the epithelial cell barrier (17). This evidence concerns the gene IFNG and colitis.